Fig. 4. PCLX-001 treatment attenuates BCR downstream signaling events in BL2 lymphoma cells.

Western blot of BL2 cells treated for 48 h with 0.1 µM or 1.0 μM of dasatinib, ibrutinib or PCLX-001 to detect total tyrosine phosphorylation (P-Tyr), Lyn, Lyn phosphorylated on tyrosine 396 or 507, BTK, and BTK phosphorylated on tyrosines 223 or 551 (a), HGAL, SYK, phosphorylated SYK (P-SYK) (b) or ERK, phosphorylated ERK (P-ERK), NFκB, c-Myc, CREB, Arf-1, BIP, and PARP-1 (c). Western blots are representative of at least three independent experiments. GAPDH serves as a loading control. BL2 cells were activated with 25 μg/ml F(ab’)₂ anti-human IgM for 2 min and processed for western blotting. All western blots shown are representative of three independent experiments. Source data are provided as a Source Data file.